Net Loss Per Share Attributable to Common Stockholders - Anti-dilutive common equivalent shares (Details) - shares
|
3 Months Ended |
Apr. 30, 2023 |
Apr. 30, 2022 |
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
| Antidilutive common equivalent shares (in shares) |
15,753,565
|
18,185,627
|
| Restricted stock and restricted stock units |
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
| Antidilutive common equivalent shares (in shares) |
10,196,611
|
10,282,007
|
| Shares estimated to be purchased under ESPP |
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
| Antidilutive common equivalent shares (in shares) |
218,750
|
340,938
|
| Performance-based restricted stock units |
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
| Antidilutive common equivalent shares (in shares) |
2,000,000
|
2,000,000
|
| Common Stock | Options to purchase common stock |
|
|
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] |
|
|
| Antidilutive common equivalent shares (in shares) |
3,338,204
|
5,562,682
|